Abstract Number: 319 • 2013 ACR/ARHP Annual Meeting
Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Background/Purpose: Since interleukin (IL)-17A has a potential role in the pathogenesis and chronic inflammation of psoriatic disease, with similar pathways impacting skin and joints, strategies…Abstract Number: 288 • 2013 ACR/ARHP Annual Meeting
MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI
Background/Purpose: : The aim of our study was to describe pelvic MRI findings of juvenile spondyloarthopathy describe the treatment effects on subsequent MRIs in juvenile…Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…Abstract Number: 281 • 2013 ACR/ARHP Annual Meeting
GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m2 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
GO-KIDS Imaging Substudy: MRI treatment response to 30 mg/m2 4-weekly subcutaneous injections of Golimumab in children with polyarticular JIA– preliminary results of the open label…Abstract Number: 282 • 2013 ACR/ARHP Annual Meeting
Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy
Background/Purpose: Combination therapy of tumor necrosis factor inhibitors (TNFi) and methotrexate (MTX) is a well-established treatment that has dramatically changed outcomes in Juvenile Idiopathic Arthritis…Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…Abstract Number: 284 • 2013 ACR/ARHP Annual Meeting
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Background/Purpose: The ACR has endorsed a core set of six measures to assess the course of JIA and the impact of treatment: active joint count,…Abstract Number: 285 • 2013 ACR/ARHP Annual Meeting
Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis
Background/Purpose: Previous literature supports an increase in cardiovascular (CV) morbidity and mortality in adults with inflammatory joint disease, however it is not known whether children with…Abstract Number: 286 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis
Background/Purpose: Increased cardiovascular mortality and morbidity have been observed in adults with Rheumatoid Arthritis. The long-term risk of cardiovascular disease for individuals with Juvenile Idiopathic…Abstract Number: 287 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
Background/Purpose: Subclinical cardiac involvement was previously described in juvenile idiopathic arthritis (JIA) patients, however there is no data regarding echocardiography and cardiac biomarkers evaluations in…Abstract Number: 289 • 2013 ACR/ARHP Annual Meeting
Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score
Background/Purpose: A new approach to the measurement of disease activity in juvenile idiopathic arthritis (JIA) is based on the Juvenile Arthritis Disease Activity Score (JADAS).…Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…Abstract Number: 292 • 2013 ACR/ARHP Annual Meeting
Body Surface Area-Based Dosing Approach Produced Comparable Golimumab Exposure Across Different Age Ranges After Subcutaneous Administration Of Golimumab In Pediatric Patients With Juvenile Idiopathic Arthritis
Background/Purpose: To evaluate the pharmacokinetics (PK) of body surface area (BSA)-adjusted dosing of SC golimumab 30 mg/m2 every 4 weeks (q4w) + methotrexate (MTX)…Abstract Number: 293 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
Background/Purpose: Lack of efficacy of Methotrexate, primary and secondary resistance to biologics and their intolerance lead to juvenile idiopathic arthritis (JIA) of progression. Therefore, the problem of…Abstract Number: 294 • 2013 ACR/ARHP Annual Meeting
Physical Activity In Children With Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise, Activity and Pathophysiology in Childhood Arthritis) Study
Background/Purpose: Although children with JIA have lower fitness levels than healthy peers, little is known about their level of habitual physical activity. The LEAP…